Vaccine-Induced Immunity
Vaccine-induced immunity is the artificial induction of immunity to specific diseases by making the people immune to disease by means other than waiting for them to catch the infection. Vaccine-induced immunity has been assessed for various infections which also include HIV-1. The incidence of HIV infection is higher in vaccine treated than in placebo-treated men with pre-existing adenovirus serotype 5 immunity.
Related Conference of Vaccine-Induced Immunity
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Vaccine-Induced Immunity Conference Speakers
Recommended Sessions
- Allergy & Asthma Vaccines
- Antibodies Research
- Chicken Pox Vaccines
- Clinical Immunology & Immunopathology
- Flu Vaccines
- HIV Vaccines
- HPV Vaccines
- Immune System Disorders
- Immunization Challenges
- Immunology
- Infectious and Non-infectious diseases Vaccines
- Onco-Immunology
- Paediatric Vaccines
- Pediatric Immunology
- Plant Vaccines & Veterinary Vaccines
- Recombinant Vaccines
- Stem Cell Immunology
- Therapeutic Cancer Vaccines
- Transplant Immunology
- Travel & Edible Vaccinations
- Vaccine Types
- Vaccine-Induced Immunity
- Vaccines
- Vaccines and Immunology Advancements
- Vaccines Efficacy and Safety
- Zika Virus Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Veterinary Vaccines - Euro Vaccines 2025 (France)